Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21961927 | 0.90 | SLC7A5 (0.36) | SLC7A5STAT3CA12CA1CA2 | |
| SCHEMBL12221596 | 0.86 | SLC7A5 (0.41) | SLC7A5STAT3CA12CA1CA2 | |
| SCHEMBL16237544 | 0.84 | POLB (0.47) | — | |
| SCHEMBL10081773 | 0.81 | KMO (0.47) | MAPK14RXRA | |
| SCHEMBL1016231 | 0.77 | SLC7A5 (0.39) | SLC7A5STAT3CA12CA1CA2 | |
| SCHEMBL2344130 | 0.76 | SLC7A5 (0.52) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL8111051 | 0.74 | SLC7A5 (0.48) | SLC7A5RXRA | |
| SCHEMBL1410040 | 0.73 | KMO (0.55) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL1854635 | 0.73 | DHODH (0.48) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL110296 | 0.72 | SLC7A5 (0.58) | SLC7A5STAT3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218754-B1 | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3880197-B9 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4556008-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3470063-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMA (US) | 2025-01-01 | — | — | EP | disclosed |
| US-12065432-B2 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230364073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-16 | — | — | US | disclosed |
| EP-2914248-B2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-4218754-A2 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3880197-B1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2010037066-A2 | DOSAGE UNITS OF 3-(6-(1-(2,2-DIFLUOROBENZO [D] [1,3] DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100036130-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090176989-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176839-A1 | FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090170905-A1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-02 | — | — | US | disclosed |
| WO-2009076142-A2 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXIAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009073757-A1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3] DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20080286204-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-20080286204-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-20080286204-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065432-B2 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CALU, CA5B | SLC7A5 2350/4885STAT3 2689/4885CA12 164/4885 |
| US-20090176989-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | SLC7A5 3606/4885STAT3 3888/4885CA12 1545/4885 |
| US-20080286204-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | SLC7A5 350/4885STAT3 2240/4885CA12 4614/4885 |
| US-20100036130-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | SLC7A5 3606/4885STAT3 3888/4885CA12 1545/4885 |
| US-20230364073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | CFTR, CLCN2, CLIC1 | SLC7A5 1417/4885STAT3 2210/4885CA12 3757/4885 |
| US-20090170905-A1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CALU, CA5B | SLC7A5 2350/4885STAT3 2689/4885CA12 164/4885 |
| US-20090176839-A1 | FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID | DDC, P2RX6, CTSC | SLC7A5 3569/4885STAT3 3942/4885CA12 3036/4885 |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | CFTR, MFAP1, CMA1 | SLC7A5 3202/4885STAT3 4513/4885CA12 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.